Targeting androgen receptor stability and degradation: approaches for developing a therapy for spinal and bulbar

Riccardo Cristofani1, Barbara Tedesco2, Veronica Ferrari2

  • 1Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy. riccardo.cristofani@unimi.it.

Insights

Protein misfolding and impaired quality control cause diseases like spinal and bulbar muscular atrophy (SBMA). Targeting the protein quality control system may offer new treatments for SBMA by reducing toxic protein accumulation.

Area of Science:

  • Molecular biology
  • Cellular biology
  • Neuroscience

Background:

  • Protein misfolding and aggregation are implicated in various diseases.
  • The cellular Protein Quality Control (PQC) system manages misfolded proteins.
  • Impairment of the PQC system contributes to neurodegenerative disorders such as spinal and bulbar muscular atrophy (SBMA).

Purpose of the Study:

  • To summarize the mechanisms governing androgen receptor (AR) protein stability and degradation.
  • To review the role of the PQC system in the pathogenesis of SBMA.
  • To explore potential therapeutic strategies for SBMA targeting PQC modulation.

Main Methods:

  • Literature review of protein folding dynamics.
  • Analysis of PQC system involvement in SBMA.
  • Overview of therapeutic interventions for SBMA.

Main Results:

  • AR protein stability and degradation are tightly regulated under physiological conditions.
  • Misfolded expanded AR (ARexp) accumulates in SBMA due to PQC system dysfunction.
  • PQC system modulation presents a promising therapeutic avenue for SBMA.

Conclusions:

  • Understanding AR protein dynamics and PQC function is crucial for SBMA research.
  • Targeting the PQC system offers a potential strategy to mitigate ARexp toxicity in SBMA.
  • Further research into PQC modulation could lead to novel SBMA treatments.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
713
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K